Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3253487 | 0.80 | PLCG1 (1.00) | PLCG1CA2MMP2CA12CA9 | |
| SCHEMBL9704914 | 0.78 | PLCG1 (0.70) | PLCG1CA2MMP2CA12CA9 | |
| SCHEMBL5375 | 0.78 | PLCG1 (0.70) | PLCG1CA2MMP2CA12CA9 | |
| SCHEMBL13926097 | 0.77 | PLCG1 (0.55) | PLCG1CA2KMT2ACYP3A4CYP2C9 | |
| SCHEMBL8488156 | 0.76 | PLCG1 (0.67) | PLCG1CA2MMP2CA12CA9 | |
| SCHEMBL11376482 | 0.76 | GAA (0.61) | CA2MMP2CA12CA9CA1 | |
| SCHEMBL14393403 | 0.76 | ENPP2 (0.50) | PLCG1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL165340 | 0.76 | PLCG1 (0.67) | PLCG1CA2MMP2CA12CA9 | |
| SCHEMBL13825881 | 0.76 | PLCG1 (0.67) | PLCG1CA2MMP2CA12CA9 | |
| SCHEMBL3628081 | 0.76 | ALDH1A1 (0.61) | CA2MMP2CA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| EP-2089365-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008045668-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | PLCG1 4278/4885CA2 615/4885MMP2 16/4885 |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | PLCG1 4278/4885CA2 615/4885MMP2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.